Samalizumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Samalizumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
TargetCD200
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6542H10086N1702O2102S46
Molar mass147.7 kg/mol g·mol−1
 ☒N☑Y (what is this?)  (verify)

Samalizumab is a humanized monoclonal antibody designed for oncology indications.[1]

Samalizumab was developed by Alexion Pharmaceuticals.

References[edit]

  1. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Samalizumab" (PDF). American Medical Association.